* Annovis Bio Inc ANVS.N ANVS.K is expected to report
results on August 7 (estimated).
*
* Refinitiv's mean analyst estimate for Annovis Bio Inc is
for a
loss of $1.14 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Annovis Bio
Inc
is $40, above its last closing price of $13.07.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.33 -0.33 -1.19 Missed -256.3
Dec. 31 2023 -1.05 -1.05 -0.38 Beat 63.9
Sep. 30 2022 -1.02 -1.01 -0.93 Beat 8.2
Jun. 30 2022 -0.65 -0.64 -1.07 Missed -65.9
Mar. -0.58 -0.58 -0.72 Missed -24.1
31 2022
Dec. 31 2021 -0.25 -0.25 -0.75 Missed -200
Sep. 30 2021 -0.44 -0.44 -0.35 Beat 20.5
Jun. 30 2021 -0.37 -0.37 -0.34 Beat 8.1
This summary was machine generated August 4 at 18:36 GMT. All
figures in US dollars unless otherwise stated